Solasia Files for China-Japan Trials of Oral Mucositis Treatment

Solasia Pharma, a Japanese pharma that in-licenses western oncology treatments for use in Asia, has filed a New Medical Device Application for episil ® (SP-03) in China and Japan. Episil is an oral treatment for pain associated with oral mucositis. One year ago, Solasia acquired rights to episil for Japan and China from Camurus, a Swedish company that uses lipid-based nanotechnology to deliver drugs. Episil forms a bioadhesive film that coats intra-oral mucosal surfaces, protecting them. More details.... Share this with colleagues: // //